Table 1 Clinical characteristics of patients in our cohort (n = 82)
From: Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury
Characteristic | No. of patients (%) |
|---|---|
Mean age (standard deviation) | 57 years (14) |
Male sex | 54 (66) |
Race/ethnicity | |
 White | 63 (77) |
 Black | 7 (9) |
 Hispanic | 9 (11) |
 Other | 3 (4) |
Baseline risk factors | |
 History of smoking | 35 (43) |
 Alcohol consumption | 35 (43) |
 Type II diabetes mellitus | 21 (26) |
 Drug allergy | 51 (62) |
 Prior history of pancreatitis | 7 (9) |
 Pancreatic metastasis | 11 (13) |
Cancer type | |
 Melanoma | 30 (37) |
 Genitourinary | 24 (29) |
 Lung, head and neck | 11 (13) |
 Gastrointestinal | 5 (6) |
 Other solid tumors | 5 (6) |
 Hematologic malignancies | 7 (9) |
Cancer stagea | |
 Stage III | 3 (4) |
 Stage IV | 72 (96) |
Median number of immune checkpoint inhibitor doses (interquartile range) | 4 (1-25) |
Checkpoint inhibitor type | |
 CTLA-4 monotherapy | 12 (15) |
 PD-1/L1 monotherapy | 53 (65) |
 Combination therapyb | 17 (21) |
Other immune-related adverse events | |
 Gastrointestinal | 27 (33) |
 Hepatic | 17 (21) |
 Dermatologic | 13 (16) |
 Endocrine | 7 (9) |
 Pulmonary | 5 (6) |
 Other | 6 (7) |